Compared with either agent alone, the combination of aliskiren and valsartan at maximum recommended doses provides significantly greater reductions in blood pressure in patients with hypertension (high blood pressure).

Aliskiren and Valsartan are both inhibitors of the renin system of the kidneys.

[Renin is a vasoconstricting substance (one which constricts the blood vessels and thus increases blood pressure), and thus inhibition of the renin system lowers blood pressure in individuals with high blood pressure.]

A study conducted by Professor Suzanne Oparil of University of Alabama at Birmingham and colleagues found that aliskiren 150mg and valsartan 160mg once daily resulted to a mean drop in their sitting diastolic blood pressure of 12.2mm Hg, compared to 9.0mm Hg decrease with once-daily aliskiren 150mg, 9.7mm Hg decrease with once-daily valsartan 160mg, and 4.1mm Hg decrease with placebo.

The researchers concluded:

"These findings provide a clear rationale for further studies to investigate the potential effects of long-term treatment with the combination of aliskiren and valsartan, and combinations of aliskiren with other angiotensin receptor blockers, on possible benefits beyond treating hypertension.

...and warned:

"Because of potential life-threatening side effects, which require biochemical monitoring, this concept of treatment is unlikely to make to general practice or even to primary prevention in specialist care."

Results of the abovementioned study are reported in an article in The Lancet.

Aliskiren is sold under the brand name Tekturna® while valsartan under the brand name Diovan®, both products of Novartis.

Find more details from the full report.